LUC7L3

Across TCGA pan-cancer cohorts, LUC7L3 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of LUC7L3’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LUC7L3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LUC7L3 is over-expressed in tumor, although a few such as KICH and UCEC show the opposite, repressed pattern.

LIHC, HNSC, and KICH are the cancer types where LUC7L3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LUC7L3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.184	<.001	9	view →
HNSC	All	All	+0.412	<.001	8	view →
KICH	Female	All	−1.455	<.001	7	view →
STAD	All	IV	+0.786	.001	6	view →
BLCA	All	All	+0.389	.003	6	view →
COAD	Male	II,III,IV	+0.632	.001	4	view →
CHOL	All	All	+2.288	<.001	3	view →
KIRC	All	All	+0.197	.011	3	view →
READ	All	All	+0.713	.020	2	view →
UCEC	All	All	−0.394	.035	2	view →
THCA	Male	IV	−0.459	.041	1	view →
LUAD	All	All	+0.290	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

LUC7L3–LIHC

Open the LIHC breakdown →